Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.